Apexigen (APGN) News Today → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free APGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completedseekingalpha.com - September 7 at 8:34 AMmarketbeat.com - August 23 at 6:04 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, CPRI, APGNmarkets.businessinsider.com - August 11 at 3:47 PMApexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meetingfinance.yahoo.com - June 3 at 8:10 AMEF Hutton Reiterates Apexigen (APGN) Hold Recommendationmsn.com - May 27 at 10:06 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGNmarkets.businessinsider.com - May 24 at 2:58 PMEF Hutton Maintains Apexigen (APGN) Buy Recommendationmsn.com - May 17 at 3:48 AMAPG SGA S.A.wsj.com - May 16 at 3:58 AMAre Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?finance.yahoo.com - March 3 at 3:18 PMAre Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?finance.yahoo.com - March 3 at 3:18 PMApexigen Announces Review of Strategic Alternatives and Restructuringfinance.yahoo.com - February 27 at 10:48 AMApexigen Announces Approximately $2.8 Million Private Placement Financingfinance.yahoo.com - January 24 at 8:56 AMWhy Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarketmsn.com - January 23 at 10:11 AMApexigen Touts New Positive Sotigalimab Data Showing Expanded Anti-Tumor Responsesfinance.yahoo.com - January 19 at 5:41 PMThinking about buying stock in Zymeworks, CureVac, Apexigen, Gamida Cell, or Xos?benzinga.com - January 19 at 12:36 PMApexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023finance.yahoo.com - January 19 at 12:36 PMApexigen Shares Halted On Circuit Breaker To The Upside, Stock Now Up 140.5%benzinga.com - January 11 at 11:38 PMmarketbeat.com - January 9 at 3:24 PMmarketbeat.com - January 9 at 9:50 AMmarketbeat.com - January 9 at 9:44 AMApexigen Reports Third Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - November 15 at 11:20 AMApexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meetingfinance.yahoo.com - November 11 at 9:55 AMHow biotech companies are building drug pipelines with PIPEsbizjournals.com - November 4 at 5:09 AMWall Street Set to Open Lower as Higher-Than-Expected UK Inflation Rattles Investorsmsn.com - October 19 at 10:00 AMApexigen, Inc. (APGN)ca.finance.yahoo.com - October 6 at 2:06 PMApexigen's Shares Fall After Data From Gastric Cancer Candidatefinance.yahoo.com - September 12 at 4:32 PMApexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022finance.yahoo.com - September 10 at 9:26 AMApexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 7 at 10:48 AMApexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022finance.yahoo.com - September 5 at 8:59 AMApexigen, Inc. Rings the Closing Bellnasdaq.com - September 2 at 6:11 PMmarketbeat.com - August 26 at 10:15 AMmarketbeat.com - August 19 at 2:11 PMApexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conferencefinance.yahoo.com - August 16 at 4:41 PMIs Apexigen (NASDAQ:APGN) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - August 16 at 4:41 PMmarketbeat.com - August 12 at 11:19 AMmarketbeat.com - August 12 at 11:13 AMmarketbeat.com - August 2 at 2:18 PMmarketbeat.com - August 1 at 10:59 AMmarketbeat.com - August 1 at 10:45 AMmarketbeat.com - August 1 at 10:32 AMmarketbeat.com - August 1 at 10:27 AMmarketbeat.com - August 1 at 10:02 AMmarketbeat.com - August 1 at 9:37 AM Get Apexigen News Delivered to You Automatically Sign up to receive the latest news and ratings for APGN and its competitors with MarketBeat's FREE daily newsletter. Email Address The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about... Click here to see Louis' new video for yourself. APGN Media Mentions By Week APGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGN News Sentiment▼0.000.46▲Average Medical News Sentiment APGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGN Articles This Week▼00▲APGN Articles Average Week Get Apexigen News Delivered to You Automatically Sign up to receive the latest news and ratings for APGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATHE News Today AEZS News Today MBRX News Today GRTX News Today BFRI News Today AKTX News Today GHSI News Today ADIL News Today ELAB News Today PPBT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APGN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apexigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
